37772 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices 

INTERNATIONAL TRADE 

COMMISSION 

[USITC SE–14–023] 

Sunshine Act Meetings 

AGENCY HOLDING THE MEETING: United 

States International Trade Commission. 

TIME AND DATE: July 11, 2014 at 11 a.m. 

PLACE: Room 101, 500 E Street SW., 

Washington, DC 20436, Telephone: 

(202) 205–2000. 

STATUS: Open to the public. 

MATTERS TO BE CONSIDERED: 

1. Agendas for future meetings: None. 

2. Minutes. 

3. Ratification List. 

4. Vote in Inv. Nos. 701–TA–515–521 

and 731–TA–1251–1257 

(Preliminary)(Certain Steel Nails from 

India, Korea, Malaysia, Oman, Taiwan, 

Turkey, and Vietnam). The Commission 

is currently scheduled to complete and 

file its determinations on July 14, 2014; 

views of the Commission are currently 

scheduled to be completed and filed on 

July 21, 2014. 

5. Outstanding action jackets: None. 

In accordance with Commission 

policy, subject matter listed above, not 

disposed of at the scheduled meeting, 

may be carried over to the agenda of the 

following meeting. 

By order of the Commission: 

Issued: June 30, 2014. 

William R. Bishop, 

Supervisory Hearings and Information 

Officer. 

[FR Doc. 2014–15679 Filed 6–30–14; 4:15 pm] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–393] 

Proposed Aggregate Production 

Quotas for Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2015 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: The Drug Enforcement 

Administration proposes to establish the 

2015 aggregate production quotas for 

controlled substances in schedules I and 

II of the Controlled Substances Act and 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

DATES: Interested persons may file 

written comments on this notice in 

accordance with 21 CFR 1303.11(c) and 

1315.11(d). Electronic comments must 

be submitted, and written comments 

must be postmarked, on or before 

August 1, 2014. Commenters should be 

aware that the electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–393’’ on all electronic and 

written correspondence. The DEA 

encourages that all comments be 

submitted electronically through the 

Federal eRulemaking Portal which 

provides the ability to type short 

comments directly into the comment 

field on the Web page or attach a file for 

lengthier comments. Please go to http: 

//www.regulations.gov and follow the 

online instructions at that site for 

submitting comments. Paper comments 

that duplicate electronic submissions 

are not necessary. Should you, however, 

wish to submit written comments, in 

lieu of electronic comments, they 

should be sent via regular or express 

mail to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Erika Gehrmann, Office of Diversion 

Control, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, Virginia 22152, Telephone: 

(202) 598–6812. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received in response to this docket are 

considered part of the public record and 

will be made available for public 

inspection online at http://

www.regulations.gov. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

The Freedom of Information Act 

(FOIA) applies to all comments 

received. If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want made publicly 

available in the first paragraph of your 

comment and identify what information 

you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify the confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be made publicly available. 

Comments containing personal 

identifying information or confidential 

business information identified as 

directed above will be made publicly 

available in redacted form. 

An electronic copy of this document 

is available at http://

www.regulations.gov for easy reference. 

If you wish to personally inspect the 

comments and materials received or the 

supporting documentation the DEA 

used in preparing the proposed action, 

these materials will be available for 

public inspection by appointment. To 

arrange a viewing, please see the FOR

FURTHER INFORMATION CONTACT

paragraph above. 

Legal Authority 

Section 306 of the Controlled 

Substances Act (CSA), 21 U.S.C. 826, 

requires the Attorney General to 

determine the total quantity and 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

and for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. This 

responsibility has been delegated to the 

Administrator of the DEA pursuant to 

28 CFR 0.100(b). The Administrator, in 

turn, has redelegated that authority to 

the Deputy Administrator, pursuant to 

28 CFR part 0 subpart R, App. 

Analysis for Proposed 2015 Aggregate 

Production Quotas and Assessment of 

Annual Needs 

The proposed year 2015 aggregate 

production quotas and assessment of 

annual needs represent those quantities 

of schedule I and II controlled 

substances, and the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine, to be 

manufactured in the United States in 

2015 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, 

lawful export requirements, and the 

establishment and maintenance of 

reserve stocks. These quotas include 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices 37773 

imports of ephedrine, pseudoephedrine, 

and phenylpropanolamine but do not 

include imports of controlled 

substances necessary to provide for the 

medical, scientific, or other legitimate 

needs of the United States. 

In determining the proposed 2015 

aggregate production quotas and 

assessment of annual needs, the DEA 

has taken into account the criteria that 

the DEA is required to consider in 

accordance with 21 U.S.C. 826(a), 21 

CFR 1303.11 (aggregate production 

quotas for controlled substances), and 

21 CFR 1315.11 (assessment of annual 

needs for ephedrine, pseudoephedrine, 

and phenylpropanolamine). The DEA 

proposes the aggregate production 

quotas and assessment of annual needs 

for 2015 by considering: (1) Total net 

disposal of the class or chemical by all 

manufacturers and chemical importers 

during the current and two preceding 

years; (2) trends in the national rate of 

net disposal of the class or chemical; (3) 

total actual (or estimated) inventories of 

the class or chemical and of all 

substances manufactured from the class 

or chemical, and trends in inventory 

accumulation; (4) projected demand for 

such class or chemical as indicated by 

procurement and chemical import 

quotas requested in accordance with 21 

CFR 1303.12, 1315.32, and 1315.34; and 

(5) other factors affecting the medical, 

scientific, research, and industrial needs 

in the United States, lawful export 

requirements, and reserve stocks, as the 

Deputy Administrator finds relevant. 

Other factors the DEA considered in 

calculating the aggregate production 

quotas, but not the assessment of annual 

needs, include product development 

requirements of both bulk and finished 

dosage form manufacturers, and other 

pertinent information. In determining 

the proposed 2015 assessment of annual 

needs, the DEA used the calculation 

methodology previously described in 

the 2010 and 2011 assessment of annual 

needs (74 FR 60294, Nov. 20, 2009, and 

75 FR 79407, Dec. 20, 2010, 

respectively). 

The DEA also specifically considered 

that inventory allowances granted to 

individual manufacturers may not 

always result in the availability of 

sufficient quantities to maintain an 

adequate reserve stock pursuant to 21 

U.S.C. 826(a), as intended. See 21 CFR 

1303.24. This would be concerning if a 

natural disaster or other unforeseen 

event resulted in substantial disruption 

to the amount of controlled substances 

available to provide for legitimate 

public need. As such, the DEA proposes 

to include in all schedule II aggregate 

production quotas, and certain schedule 

I aggregate production quotas (gammahydroxybutyric acid and 

tetrahydrocannabinols), an additional 

25% of the estimated medical, 

scientific, and research needs as part of 

the amount necessary to ensure the 

establishment and maintenance of 

reserve stocks. The resulting established 

aggregate production quotas will reflect 

these included amounts. This action 

will not affect the ability of 

manufacturers to maintain inventory 

allowances as specified by regulation. 

The DEA expects that maintaining this 

reserve in certain established aggregate 

production quotas will mitigate adverse 

public effects if an unforeseen event 

resulted in substantial disruption to the 

amount of controlled substances 

available to provide for legitimate 

public need, as determined by the DEA. 

The DEA does not anticipate utilizing 

the reserve in the absence of these 

circumstances. 

The Deputy Administrator, therefore, 

proposes to establish the 2015 aggregate 

production quotas for the following 

schedule I and II controlled substances 

and assessment of annual needs for the 

list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, as 

follows: 

Basic class 

Proposed established 2015 

quotas (g) 

Schedule I 

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ................................................................................... 15 

[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ..................................................................... 15 

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) ....................................................................................................... 15 

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) ................................................................................................... 15 

1-(1-Phenylcyclohexyl)pyrrolidine ........................................................................................................................................................ 10 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................................................ 45 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ........................................................................................................................... 45 

1-[1-(2-Thienyl)cyclohexyl]piperidine ................................................................................................................................................... 15 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ............................................................................................................... 45 

1-Butyl-3-(1-naphthoyl)indole (JWH-073) ............................................................................................................................................ 45 

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ........................................................................................... 45 

1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ........................................................................................................................................... 45 

1-Methyl-4-phenyl-4-propionoxypiperidine ........................................................................................................................................... 2 

1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ...................................................................................................................... 45 

1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ............................................................................................................................ 45 

1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ........................................................................................................................ 45 

1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ............................................................................................................................ 45 

1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ........................................................................................................................... 45 

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) .................................................................................................................... 45 

1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) ....................................................................................................................... 45 

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ...................................................................................................................... 30 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ........................................................................................................................... 30 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ........................................................................................................................ 30 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) .......................................................................................................................... 30 

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ....................................................................................................................................... 30 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ........................ 15 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ........................................................................................................................ 30 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ........................ 15

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) .............................................................................................................................. 30 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) .................................. 15 

2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ......................................................................................................................... 15 

mstockstill on DSK4VPTVN1PROD with NOTICES

37774 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices 

Basic class 

Proposed established 2015 

quotas (g) 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ...................................................................................................................................... 25 

2,5-Dimethoxy-4-n-propylthiophenethylamine ..................................................................................................................................... 25 

2,5-Dimethoxyamphetamine ................................................................................................................................................................ 25 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ................................................................................................................ 30 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) .......................................................................................................... 30 

3,4,5-Trimethoxyamphetamine ............................................................................................................................................................ 25 

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................ 55 

3,4-Methylenedioxymethamphetamine (MDMA) ................................................................................................................................. 50 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ............................................................................................................................. 40 

3,4-Methylenedioxy-N-methylcathinone (methylone) .......................................................................................................................... 50 

3,4-Methylenedioxypyrovalerone (MDPV) ........................................................................................................................................... 35 

3-Fluoro-N-methylcathinone (3-FMC) .................................................................................................................................................. 15 

3-Methylfentanyl ................................................................................................................................................................................... 2 

3-Methylthiofentanyl ............................................................................................................................................................................. 2 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ...................................................................................................................................... 25 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) .................................................................................................................................. 25 

4-Fluoro-N-methylcathinone (4-FMC) .................................................................................................................................................. 15 

4-Methoxyamphetamine ...................................................................................................................................................................... 100 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ...................................................................................................................................... 25 

4-Methylaminorex ................................................................................................................................................................................ 25 

4-Methyl-N-ethylcathinone (4-MEC) .................................................................................................................................................... 15 

4-Methyl-N-methylcathinone (mephedrone) ........................................................................................................................................ 45 

4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP) ........................................................................................................................ 15 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ......................................................................................................... 68 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ........................... 53 

5-Methoxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 25 

5-Methoxy-N,N-diisopropyltryptamine .................................................................................................................................................. 25 

5-Methoxy-N,N-dimethyltryptamine ..................................................................................................................................................... 25 

Acetyl-alpha-methylfentanyl ................................................................................................................................................................. 2 

Acetyldihydrocodeine ........................................................................................................................................................................... 2 

Acetylmethadol .................................................................................................................................................................................... 2 

Allylprodine .......................................................................................................................................................................................... 2 

Alphacetylmethadol .............................................................................................................................................................................. 2 

alpha-Ethyltryptamine .......................................................................................................................................................................... 25 

Alphameprodine ................................................................................................................................................................................... 2 

Alphamethadol ..................................................................................................................................................................................... 2 

alpha-Methylfentanyl ............................................................................................................................................................................ 2 

alpha-Methylthiofentanyl ...................................................................................................................................................................... 2 

alpha-Methyltryptamine (AMT) ............................................................................................................................................................ 25 

alpha-Pyrrolidinobutiophenone (a-PBP) .............................................................................................................................................. 15 

alpha-Pyrrolidinopentiophenone (a-PVP) ............................................................................................................................................ 15 

Aminorex .............................................................................................................................................................................................. 25 

Benzylmorphine ................................................................................................................................................................................... 2 

Betacetylmethadol ............................................................................................................................................................................... 2 

beta-Hydroxy-3-methylfentanyl ............................................................................................................................................................ 2 

beta-Hydroxyfentanyl ........................................................................................................................................................................... 2 

Betameprodine ..................................................................................................................................................................................... 2 

Betamethadol ....................................................................................................................................................................................... 4 

Betaprodine .......................................................................................................................................................................................... 2 

Bufotenine ............................................................................................................................................................................................ 3 

Cathinone ............................................................................................................................................................................................. 70 

Codeine methylbromide ....................................................................................................................................................................... 5 

Codeine-N-oxide .................................................................................................................................................................................. 200 

Desomorphine ...................................................................................................................................................................................... 5 

Diethyltryptamine ................................................................................................................................................................................. 25 

Difenoxin .............................................................................................................................................................................................. 50 

Dihydromorphine .................................................................................................................................................................................. 3,990,000 

Dimethyltryptamine .............................................................................................................................................................................. 35 

Dipipanone ........................................................................................................................................................................................... 5 

Fenethylline .......................................................................................................................................................................................... 5 

gamma-Hydroxybutyric acid ................................................................................................................................................................ 70,250,000 

Heroin .................................................................................................................................................................................................. 25 

Hydromorphinol .................................................................................................................................................................................... 2 

Hydroxypethidine ................................................................................................................................................................................. 2 

Ibogaine ............................................................................................................................................................................................... 5 

Lysergic acid diethylamide (LSD) ........................................................................................................................................................ 35 

Marihuana ............................................................................................................................................................................................ 21,000 

Mescaline ............................................................................................................................................................................................. 25 

Methaqualone ...................................................................................................................................................................................... 10 

Methcathinone ..................................................................................................................................................................................... 25 

Methyldesorphine ................................................................................................................................................................................. 5 

Methyldihydromorphine ........................................................................................................................................................................ 2 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices 37775 

Basic class 

Proposed established 2015 

quotas (g) 

Morphine methylbromide ..................................................................................................................................................................... 5 

Morphine methylsulfonate .................................................................................................................................................................... 5 

Morphine-N-oxide ................................................................................................................................................................................ 350 

N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ........................................................................................................ 15 

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) ..................................................... 15 

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) .......................................... 15 

N,N-Dimethylamphetamine .................................................................................................................................................................. 25 

Naphthylpyrovalerone (naphyrone) ..................................................................................................................................................... 15 

N-Benzylpiperazine .............................................................................................................................................................................. 25 

N-Ethyl-1-phenylcyclohexylamine ........................................................................................................................................................ 5 

N-Ethylamphetamine ........................................................................................................................................................................... 24 

N-Hydroxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 24 

Noracymethadol ................................................................................................................................................................................... 2 

Norlevorphanol ..................................................................................................................................................................................... 52 

Normethadone ..................................................................................................................................................................................... 2 

Normorphine ........................................................................................................................................................................................ 18 

Phenomorphan .................................................................................................................................................................................... 2 

Psilocybin ............................................................................................................................................................................................. 30 

Psilocyn ................................................................................................................................................................................................ 30 

Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ........................................................................ 15 

Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ........................................................................................................ 15 

Tetrahydrocannabinols ........................................................................................................................................................................ 497,500 

Thiofentanyl ......................................................................................................................................................................................... 2 

Tilidine .................................................................................................................................................................................................. 10 

Trimeperidine ....................................................................................................................................................................................... 2 

Schedule II 

1-Phenylcyclohexylamine .................................................................................................................................................................... 5 

1-Piperidinocyclohexanecarbonitrile .................................................................................................................................................... 5 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ......................................................................................................................................... 2,687,500 

Alfentanil .............................................................................................................................................................................................. 17,625 

Alphaprodine ........................................................................................................................................................................................ 3 

Amobarbital .......................................................................................................................................................................................... 25,125 

Amphetamine (for conversion) ............................................................................................................................................................ 21,875,000 

Amphetamine (for sale) ....................................................................................................................................................................... 37,500,000 

Carfentanil ............................................................................................................................................................................................ 19 

Cocaine ................................................................................................................................................................................................ 240,000 

Codeine (for conversion) ..................................................................................................................................................................... 50,000,000 

Codeine (for sale) ................................................................................................................................................................................ 46,125,000 

Dextropropoxyphene ............................................................................................................................................................................ 19 

Dihydrocodeine .................................................................................................................................................................................... 101,375 

Diphenoxylate ...................................................................................................................................................................................... 1,337,500 

Ecgonine .............................................................................................................................................................................................. 174,375 

Ethylmorphine ...................................................................................................................................................................................... 3 

Fentanyl ............................................................................................................................................................................................... 2,108,750 

Glutethimide ......................................................................................................................................................................................... 3 

Hydrocodone (for conversion) ............................................................................................................................................................. 137,500 

Hydrocodone (for sale) ........................................................................................................................................................................ 99,625,000 

Hydromorphone ................................................................................................................................................................................... 6,250,000 

Isomethadone ...................................................................................................................................................................................... 5 

levo-Alphacetylmethadol (LAAM) ........................................................................................................................................................ 4 

Levomethorphan .................................................................................................................................................................................. 5 

Levorphanol ......................................................................................................................................................................................... 3,375 

Lisdexamfetamine ................................................................................................................................................................................ 29,750,000 

Meperidine ........................................................................................................................................................................................... 6,250,000 

Meperidine Intermediate-A .................................................................................................................................................................. 6 

Meperidine Intermediate-B .................................................................................................................................................................. 11 

Meperidine Intermediate-C .................................................................................................................................................................. 6 

Metazocine ........................................................................................................................................................................................... 19 

Methadone (for sale) ........................................................................................................................................................................... 31,875,000 

Methadone Intermediate ...................................................................................................................................................................... 34,375,000 

Methamphetamine ............................................................................................................................................................................... 2,061,375 

[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for 

conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]. 

Methylphenidate ................................................................................................................................................................................... 83,750,000 

Morphine (for conversion) .................................................................................................................................................................... 91,250,000 

Morphine (for sale) .............................................................................................................................................................................. 62,500,000 

Nabilone ............................................................................................................................................................................................... 18,750 

Noroxymorphone (for conversion) ....................................................................................................................................................... 17,500,000 

mstockstill on DSK4VPTVN1PROD with NOTICES

37776 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices 

Basic class 

Proposed established 2015 

quotas (g) 

Noroxymorphone (for sale) .................................................................................................................................................................. 1,475,000 

Opium (powder) ................................................................................................................................................................................... 112,500 

Opium (tincture) ................................................................................................................................................................................... 687,500 

Oripavine .............................................................................................................................................................................................. 22,750,000 

Oxycodone (for conversion) ................................................................................................................................................................ 8,350,000 

Oxycodone (for sale) ........................................................................................................................................................................... 137,500,000 

Oxymorphone (for conversion) ............................................................................................................................................................ 21,875,000 

Oxymorphone (for sale) ....................................................................................................................................................................... 7,750,000 

Pentobarbital ........................................................................................................................................................................................ 35,000,000 

Phenazocine ........................................................................................................................................................................................ 6 

Phencyclidine ....................................................................................................................................................................................... 19 

Phenmetrazine ..................................................................................................................................................................................... 3 

Phenylacetone ..................................................................................................................................................................................... 9,375,000 

Racemethorphan ................................................................................................................................................................................. 3 

Remifentanil ......................................................................................................................................................................................... 3,750 

Secobarbital ......................................................................................................................................................................................... 215,003 

Sufentanil ............................................................................................................................................................................................. 6,255 

Tapentadol ........................................................................................................................................................................................... 12,500,000 

Thebaine .............................................................................................................................................................................................. 125,000,000 

List I Chemicals 

Ephedrine (for conversion) .................................................................................................................................................................. 1,000,000 

Ephedrine (for sale) ............................................................................................................................................................................. 3,000,000 

Phenylpropanolamine (for conversion) ................................................................................................................................................ 44,800,000 

Phenylpropanolamine (for sale) ........................................................................................................................................................... 8,500,000 

Pseudoephedrine (for conversion) ...................................................................................................................................................... 7,000 

Pseudoephedrine (for sale) ................................................................................................................................................................. 224,500,000 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedule I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. Pursuant to 21 CFR 1303.13 and 21 

CFR 1315.13, upon consideration of the 

relevant factors, the Deputy 

Administrator may adjust the 2015 

aggregate production quotas and 

assessment of annual needs as 

necessary. 

Comments 

In accordance with 21 CFR 1303.11(c) 

and 1315.11(d), any interested person 

may submit written comments on or 

objections to these proposed 

determinations. Based on comments 

received in response to this notice, the 

Deputy Administrator may hold a 

public hearing on one or more issues 

raised. 21 CFR 1303.11(c) and 

1515.11(e). In the event the Deputy 

Administrator decides to hold such a 

hearing, the Deputy Administrator will 

publish a notice of the hearing in the 

Federal Register. After consideration of 

any comments or objections, or after a 

hearing, if one is held, the Deputy 

Administrator will issue and publish in 

the Federal Register a final order 

establishing the 2015 aggregate 

production quota for each basic class of 

controlled substance and establishing 

the assessment of annual needs for the 

list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 21 CFR 

1303.11(c) and 1315.11(f). 

Dated: June 26, 2014. 

Thomas M. Harrigan, 

Deputy Administrator. 

[FR Doc. 2014–15549 Filed 7–1–14; 8:45 am] 

BILLING CODE 4410–09–P 

OFFICE OF MANAGEMENT AND 

BUDGET 

Draft 2014 Report to Congress on the 

Benefits and Costs of Federal 

Regulations and Unfunded Mandates 

on State, Local, and Tribal Entities 

AGENCY: Executive Office of the 

President, Office of Management and 

Budget. 

ACTION: Notice of availability and 

request for comments. 

SUMMARY: The Office of Management 

and Budget (OMB) requests comments 

on its Draft 2014 Report to Congress on 

the Benefits and Costs of Federal 

Regulations, available at: http://

www.whitehouse.gov/omb/inforeg_

regpol_reports_congress/. The Draft 

Report is divided into two parts. Part I 

contains two chapters. Chapter I 

examines the benefits and costs of major 

Federal regulations issued in fiscal year 

2013 and summarizes the benefits and 

costs of major regulations issued 

between October 2003 and September 

2013. It also discusses regulatory 

impacts on State, local, and tribal 

governments, small business, wages, 

and economic growth. Chapter II offers 

recommendations for regulatory reform. 

Part II summarizes agency compliance 

with the Unfunded Mandates Reform 

Act. 

OMB requests that comments be 

submitted electronically to OMB by 

September 2, 2014 through 

www.regulations.gov. 

DATES: To ensure consideration of 

comments as OMB prepares this Draft 

Report for submission to Congress, 

comments must be in writing and 

received by September 2, 2014. 

ADDRESSES: Submit comments by one of 

the following methods: 

• www.regulations.gov: Direct 

comments to Docket ID OMB–2014– 

0002 

• Fax: (202) 395–7285 

• Mail: Office of Information and 

Regulatory Affairs, Office of 

Management and Budget, Attn: Mabel 

Echols, NEOB, Room 10202, 725 17th 

Street NW., Washington, DC 20503. To 

ensure that your comments are received, 

we recommend that comments on this 

draft report be electronically submitted. 

All comments and recommendations 

submitted in response to this notice will 

be made available to the public, 

including by posting them on OMB’s 

Web site. For this reason, please do not 

mstockstill on DSK4VPTVN1PROD with NOTICES